Technologies
COVID vaccine boosters: When is it time for that extra shot? Here’s what we know
Officials set an initial Sept. 20 date for vaccine booster shots. We’ll update you on the White House’s booster plan and tell you what’s happening with each vaccine.
On Friday, The New York Times reported that officials from the Food and Drug Administration as well as the Centers for Disease Control and Prevention are advising the White House to scale back its original booster recommendation. Last month, President Joe Biden announced that his administration would start offering boosters to those who’d been fully immunized at least eight months ago by the Pfizer-BioNTech or Moderna vaccine. The original plan was contingent on approval by the FDA, which still says there’s not enough data on booster shots to go forward.
Government officials are now cautioning that boosters may be available just for those who received the Pfizer vaccine, because regulators may need more time to evaluate the vaccines from Moderna and Johnson & Johnson.
The booster recommendations come as research shows how the effectiveness of the vaccines can decline. An additional shot from Johnson & Johnson, Pfizer or Moderna could provide enhanced protection against the COVID-19 delta variant as it surges across the country. «Recent data makes clear that protection against mild and moderate disease has decreased over time,» US Surgeon General Vivek Murthy said during an August briefing on COVID-19 vaccines. «This is likely due to both waning immunity and the strength of the widespread delta variant.»
What does all this mean for you? Read on for what we know about COVID-19 booster shots today, including who can get them now, why they’re needed, how they relate to breakthrough infections and what the controversy has been surrounding third shots. We’ll be updating this as new information is released.
Why would a Pfizer vaccine booster be authorized first?
According to a report by The New York Times on Sept. 3, administration health officials warn that the FDA and CDC may not have enough time to approve boosters from Moderna and Johnson & Johnson in time to meet Biden’s goal of starting booster shots on Sept. 20.
While the Pfizer plan seems to remain on track, Moderna announced it just began submitting booster data to the FDA, so the process may take some more time to determine a recommended dosage for a third Moderna shot. Data from Johnson & Johnson has not yet been delivered.
Who would qualify for a booster shot and when?
In August, healthofficials in the Biden administration recommended an additionalshot for Americans 18 and over who are fully vaccinated with thePfizer or Moderna shots, proposing a booster eight months after being fully vaccinated.
During a meeting with Israeli Prime Minister Naftali Bennett at the end of August, Biden said administration health officials were evaluating a five-month gap, based in part on data from Israel’s booster program. The news followed a report by The Wall Street Journal that the Biden administration was evaluating a booster shot six months after the last jab.
Waiting months in between doses allows the immune system to develop a full response before it is helped by a boost. Whatever the time gap, the booster plan would need to be evaluated and approved by the FDA. The plan is also pendingrecommendation by the CDC’sAdvisory Committee on Immunization Practices.
«We believethat that third dose will ultimately be needed to provide the fullestand continual extent of protection that we think people need from thevirus,» Murthy said. «Our plan is to stay ahead of this virus by beingprepared to offer COVID-19 booster shots to fully vaccinated adults 18years and older.» Murthy said the FDA will evaluate booster shots forthose younger than 18 years of age, and the administration will followFDA recommendations for minors.
Does full FDA approval of Pfizer’s vaccine include a booster?
On Aug. 23, the FDA approved Pfizer’s COVID-19 vaccine for two doses for people 16 and older. The Pfizer vaccine is the first to receive FDA approval, while Moderna and Johnson & Johnson vaccines are available under an emergency use authorization. And for children ages 12 to 15, Pfizer’s vaccine is authorized for emergency use.
While a third dose for some immunocompromised individuals is authorized for emergency use, the FDA final authorization does not include a booster shot, which the Biden administration is hoping to roll out as soon as this month. But some health care experts believe the two-shot approval could give a push to those who were waiting on the FDA before getting vaccinated.
«The moment you have been waiting for is here,» Biden said, following the FDA approval. «Now it has been granted. Those who’ve been waiting for full approval should go get their shot now.»
The approval could also lead to more businesses, schools and venues mandating vaccine requirements.
What about a Johnson & Johnson vaccine booster shot?
On Aug. 25, Johnson & Johnson saida booster shot of its COVID-19 vaccine increases antibody responses inthose who received the company’s one-dose vaccine, based on interimdatafrom anearly trial. The company said it would work with public healthofficials on a plan for a booster shot for eightmonths or longerafter the first dose of its vaccine.
Currently,the one-doseJohnson & Johnson vaccine is available under anemergency useauthorization for individuals 18 years of age and older.
Bidenadministration health officials said they expect those who receivedtheone-dose Johnson & Johnson vaccine will need another jab, butmoreresearch is necessary. «We expect more data on J&Jin thecomingweeks,» Murthy said when announcing plans for booster shots in late August.»With thatdata in hand, we willkeep the public informed with thetimely plan forJ&J boostershots.»
What about those eligible for booster shots now?
Some people who already are eligible under guidelines from the CDC can go out and get their third dose of a COVID-19 vaccine immediately. The list of immunocompromised people who can get a third shot includes solid-organ transplant recipients and people who have an «equivalent level of immunocompromise» and who have a reduced ability to fight off infections, making them more vulnerable to the coronavirus. Booster authorization hasn’t yet been expanded more broadly to those with other chronic medical conditions.
The current CDC recommendation is for an additional dose of the two-shot vaccine for certain immunocompromised people. Within that category, the recommendation is for those 18 and older for the Moderna vaccine, and 12 and older for the Pfizer vaccine. The FDA didn’t authorize an additional dose of the Johnson & Johnson vaccine, and because of a lack of data the CDC hasn’t recommended a second dose for immunocompromised people who got the one-shot vaccine.
About 3% of US adults are immunocompromised, according to the CDC, but research suggests they account for about 44% of hospitalized breakthrough cases of COVID-19. Not only are they more likely to get very ill from COVID-19, they also have a lower antibody response to vaccines and are at a higher risk of transmitting the virus.
Those with other conditions, like diabetes and heart disease, aren’t advised to get a booster, at least for now. Here’s a list of people the CDC recommends get an extra dose if they got the Pfizer or Moderna vaccine:
- Those with advanced or untreated HIV infection.
- Cancer patients and transplant recipients who are taking certain immunosuppressive drugs.
- Those receiving active cancer treatment for tumors or cancers of the blood.
- Those with moderate or severe primary immunodeficiency.
- Patients being treated with high-dose corticosteroids or other drugs that may suppress immune response.
- People who received a stem cell transplant within the last two years and are taking certain drugs. The CDC says to talk to your medical provider about your health condition and whether a third shot is appropriate.
If you’re unsure whether you’re qualified, the CDC says to talk to your medical provider about your health condition and whether a third dose is appropriate.
Will the booster shots be free and available?
The current one-dose vaccine shot from Johnson & Johnson and two-dose vaccines from Moderna and Pfizer are free to anyone who wants to get vaccinated. And the additional shots will be free too. «These booster shots are free,» Biden said. «It will be easy. Just show your vaccination card and you’ll get a booster. No other ID. No insurance. No state registry requirements.»
«It will be just as easy and convenient to get a booster shot as it is to get a first shot today. We have enough vaccine supply for every American,» said White House COVID-19 Response Coordinator Jeff Zients, adding that those who are eligible will be able to get a booster at roughly 80,000 places across the country, including over 40,000 local pharmacies. Zients said 90% of Americans have a vaccine site within 5 miles of where they live.
What’s behind the need for COVID-19 booster shots?
«The COVID-19 vaccines that are authorized in the United States have been remarkably effective, even against the widespread delta variant,» Murthy said. «But we know that even highly effective vaccines become less effective over time.»
Calling the eradication of the COVID-19 virus «unlikely,» a UK scientific advisory group found (PDF) that there’s a «realistic possibility» that a variant will emerge that is resistant to the current battery of vaccines. Governments, public health organizations and vaccine makers are all tracking developments in coronavirus variants like delta and lambda, hoping to determine if booster shots targeting new variants will be needed among the general population.
What’s the relationship to COVID-19 breakthrough cases?
As of July, in the US, «breakthrough» coronavirus cases caused by the dominant delta variant amount to less than 1% of people who are fully vaccinated. Both the Moderna and Pfizer vaccines have proved to be more than 90% effective against hospitalizations and death. Nonetheless, a CDC study shows that vaccinated people can both contract the highly contagious delta variant and spread it. According to a widely reported internal CDC memo, the delta variant spreads as easily as chicken pox, which is considered more contagious than the flu but less contagious than measles.
The surge in new COVID-19 cases is primarily affecting unvaccinated people and causing community spread, and in turn, prompting the return of mask mandates and guidance in hard-hit areas, even for people who have full vaccine protection. The debate over mask use and vaccine boosters underscores how scientists and other health experts continue to grapple with the uncertainties of COVID-19.
According to Murthy, «We are concerned that this pattern of decline we are seeing will continue in the months ahead, which could lead to reduced protection against severe disease, hospitalization and death.»
What’s the global controversy over booster shots?
Israel is now administering third doses of the vaccine to those 50 and older, and the UK has similar plans for September. However, this is resulting in a backlash among countries that are struggling to deliver first and second shots to residents.
World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a «moratorium» on booster shots in high-income countries, citing the global disparity in vaccine distribution. Of the 4 billion doses administered globally, 80% have gone to high- and upper-middle income countries that make up less than half the world’s population, he said.
«We cannot accept countries that have already used most of the global supply of vaccines using even more of it, while the world’s most vulnerable people remain unprotected. We call on vaccine producers to prioritize Covax,» Tedros said, referring to the world’s COVID-19 vaccine distribution program.
White House Press Secretary Jen Psaki said on Aug. 17 that the US will have enough vaccines to both provide boosters for those who are fully vaccinated in the US and meet the global demand. «We have long planned from enough supply,» she said.
The US has so far shipped 115 million vaccine doses to 80 different countries, Zients said. «Our wartime efforts will continue doing everything we can to get even more people vaccinated both here at home and around the world. We can and must do both at the same time because that’s what it’s going to take to end this pandemic,» he said.
Is it possible to mix and match COVID-19 vaccines?
According to The New York Times, administration officials will recommend people get a booster of the same vaccine they originally received. The CDC now says a third dose of a different vaccine brand is permitted if a dose of the same type isn’t available.
Other global health agencies and countries are testing administered vaccines from two different manufacturers. In the UK, for example, a recent study found that those who received a first dose of the AstraZeneca vaccine and a second of Pfizer had a higher immune response than those who received two doses of the AstraZeneca vaccine.
While we watch how the situation develops, here’s what we know about the delta variant and info on whether you need to continue to wear a mask.
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.
Technologies
Google races to put Gemini at the center of Android before Apple’s AI reboot
Google is using its latest Android rollout to position Gemini as the AI layer across phones, Chrome, laptops and cars.
Google is using its latest Android rollout to make Gemini less of a chatbot and more of an operating layer across the phone, browser, car and laptop, just weeks before Apple is expected to show its own Gemini-powered Apple Intelligence reboot at WWDC.
Ahead of its Google I/O developer conference next week, the company previewed a number of Android updates, including AI-powered app automation, a smarter version of Chrome on Android, new tools for creators, a redesigned Android Auto experience, and a sweeping set of new security features.
Alphabet is counting on Gemini to help Google compete directly with OpenAI and Anthropic in the market for artificial intelligence models and services, while also serving as the AI backbone across its expansive portfolio of products, including Android. Meanwhile, Gemini is powering part of Apple’s new AI strategy, giving Google a role in the iPhone maker’s reset even as it races to prove its own version of personal AI on the phone is further along.
Sameer Samat, who oversees Google’s Android ecosystem, told CNBC that Google is rebuilding parts of Android around Gemini Intelligence to help users complete everyday tasks more easily.
“We’re transitioning from an operating system to an intelligence system,” he said.
As part of Tuesday’s announcements. Google said Gemini Intelligence will be able to move across apps, understand what’s on the screen and complete tasks that would normally require a user to jump between multiple services. That means Android is moving beyond the traditional assistant model, where users ask a question and get an answer, and acting more like an agent.
For instance, Google says Gemini can pull relevant information from Gmail, build shopping carts and book reservations. Samat gave the example of asking Gemini to look at the guest list for a barbecue, build a menu, add ingredients to an Instacart list and return for approval before checkout.
A big concern surrounding agentic AI involves software taking action on a user’s behalf without permissions. Samat said Gemini will come back to the user before completing a transaction, adding, “the human is always in the loop.”
Four months after announcing its Gemini deal with Google, Apple is under pressure to show a more capable version of Apple Intelligence, which has been a relative laggard on the market. Apple has long framed privacy, hardware integration and control of the user experience as its advantages.
Google’s Android push is designed to show it can bring AI deeper into the device experience while still giving users control over what Gemini can see, where it can act and when it needs confirmation.
The app automation features will roll out in waves, starting with the latest Samsung Galaxy and Google Pixel phones this summer, before expanding across more Android devices, including watches, cars, glasses and laptops later this year.
The company is also redesigning Android Auto around Gemini, turning the car into another major surface for its assistant. Android Auto is in more than 250 million cars, and Google says the new release includes its biggest maps update in a decade and Gemini-powered help with tasks like ordering dinner while driving.
Alphabet’s AI strategy has been embraced by Wall Street, which has pushed the company’s stock price up more than 140% in the past year, compared to Apple’s roughly 40% gain. Investors now want to see how Gemini can become more central to the products people use every day.
WATCH: Alphabet briefly tops Nvidia after report of $200 billion Anthropic cloud deal
Technologies
Waymo recalls 3,800 robotaxis after glitch allowed some vehicles to ‘drive into standing water’
Waymo issued a voluntary recall of about 3,800 of its robotaxis to fix software issues that could allow them to drive into flooded roadways.
Waymo is recalling about 3,800 robotaxis in the U.S. to fix software issues that could allow them to “drive onto a flooded roadway,” according to a letter on the National Highway Traffic Safety Administration’s website.
The voluntary recall is for Waymo vehicles that use the company’s fifth and sixth generation automated driving systems (or ADS), the U.S. auto safety regulator said in the letter posted Tuesday.
Waymo autonomous vehicles in Austin, Texas, were seen on camera driving onto a flooded street and stalling, requiring other drivers to navigate around them. It’s the latest example of a safety-related issue for the Alphabet-owned AV unit that’s rapidly bolstering its fleet of vehicles and entering new U.S. markets.
Waymo has drawn criticism for its vehicles failing to yield to school buses in Austin, and for the performance of its vehicles during widespread power outages in San Francisco in December, when robotaxis halted in traffic, causing gridlock.
The company said in a statement on Tuesday that it’s “identified an area of improvement regarding untraversable flooded lanes specific to higher-speed roadways,” and opted to file a “voluntary software recall” with the NHTSA.
“Waymo provides over half a million trips every week in some of the most challenging driving environments across the U.S., and safety is our primary priority,” the company said.
Waymo added that it’s working on “additional software safeguards” and has put “mitigations” in place, limiting where its robotaxis operate during extreme weather, so that they avoid “areas where flash flooding might occur” in periods of intense rain.
WATCH: Waymo launches new autonomous system in Chinese-made vehicle
Technologies
Qualcomm tumbles 13% as semiconductor stocks retreat from historic AI-fueled surge
Semiconductor equities reversed sharply after a broad AI-driven advance, with Qualcomm suffering its worst day since 2020 amid inflation concerns and rising oil prices.
Semiconductor stocks fell sharply on Tuesday, reversing course after an extensive rally that had expanded the artificial intelligence investment theme well past Nvidia and driven the industry to unprecedented levels.
Qualcomm plunged 13% and was on track for its steepest single-day decline since 2020. Intel shed 8%, while On Semiconductor and Skyworks Solutions each lost more than 6%. The iShares Semiconductor ETF, which benchmarks the overall sector, fell 5%.
The sell-off came after a key gauge of consumer prices came in above forecasts, and as conflict in Iran pushed crude oil higher—prompting investors to shift away from riskier assets.
The preceding advance had widened the AI opportunity set beyond longtime industry leader Nvidia, which for much of the past several years had largely carried the market to new peaks on its own.
Explosive appetite for central processing units, along with the graphics processing units that power large language models, has sent chipmakers to all-time highs.
Market participants are wagering that the shift from AI model training to autonomous agents will lift demand for additional AI hardware. Among the beneficiaries are memory chip producers, which are raising prices as supply remains tight.
Micron Technology slid 6%, and Sandisk cratered 8%. Sandisk’s stock has surged more than six times over since January.
-
Technologies3 года agoTech Companies Need to Be Held Accountable for Security, Experts Say
-
Technologies3 года agoBest Handheld Game Console in 2023
-
Technologies5 лет agoBlack Friday 2021: The best deals on TVs, headphones, kitchenware, and more
-
Technologies3 года agoTighten Up Your VR Game With the Best Head Straps for Quest 2
-
Technologies5 лет agoGoogle to require vaccinations as Silicon Valley rethinks return-to-office policies
-
Technologies5 лет agoVerum, Wickr and Threema: next generation secured messengers
-
Technologies4 года agoThe number of Сrypto Bank customers increased by 10% in five days
-
Technologies5 лет agoOlivia Harlan Dekker for Verum Messenger
